SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 75 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $867,000 | +182.4% | 79,000 | +125.7% | 0.02% | +400.0% |
Q4 2019 | $307,000 | +17.6% | 35,000 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $261,000 | -19.9% | 35,000 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $326,000 | -60.4% | 35,000 | -65.6% | 0.00% | -50.0% |
Q3 2018 | $823,000 | +131.8% | 101,800 | +101.6% | 0.01% | +100.0% |
Q2 2018 | $355,000 | -50.6% | 50,500 | 0.0% | 0.00% | -50.0% |
Q1 2018 | $719,000 | +62.7% | 50,500 | 0.0% | 0.01% | +60.0% |
Q4 2017 | $442,000 | -25.2% | 50,500 | 0.0% | 0.01% | -28.6% |
Q3 2017 | $591,000 | -16.2% | 50,500 | 0.0% | 0.01% | -12.5% |
Q2 2017 | $705,000 | +1.7% | 50,500 | 0.0% | 0.01% | 0.0% |
Q1 2017 | $693,000 | – | 50,500 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |